John Oyler Sells 30,520 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock
John Oyler Sells 30,520 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) CEO John Oyler sold 30,520 shares of the company's stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $153.50, for a total value of $4,684,820.00. Following the sale, the chief executive officer now owns 2,070,913 shares of the company's stock, valued at $317,885,145.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
百濟神州(納斯達克代碼：BGNE-GET Rating)首席執行官約翰·奧勒在9月20日(星期二)的一次交易中出售了30,520股票。這隻股票的平均售價為153.50美元，總價值為4,684,820.00美元。出售後，這位首席執行官現在持有該公司2,070,913股股票，價值317,885,145.50美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過此超鏈接.
BeiGene Trading Down 3.7 %
百濟神州股價下跌3.7%
BeiGene stock opened at $138.64 on Friday. The stock has a 50-day moving average of $173.46 and a two-hundred day moving average of $167.46. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.35 and a current ratio of 4.54. BeiGene, Ltd. has a one year low of $118.18 and a one year high of $392.30. The stock has a market cap of $14.37 billion, a PE ratio of -6.79 and a beta of 0.65.
百濟神州的股票週五開盤報138.64美元。該股的50日移動均線切入位在173.46美元，200日移動均線切入位在167.46美元。該公司的負債權益比率為0.03，速動比率為4.35，流動比率為4.54。百濟神州股份有限公司的一年低點為118.18美元，一年高點為392.30美元。該股市值為143.7億美元，市盈率為-6.79，貝塔係數為0.65。
BeiGene (NASDAQ:BGNE – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported ($5.56) EPS for the quarter, missing analysts' consensus estimates of ($4.23) by ($1.33). BeiGene had a negative net margin of 187.65% and a negative return on equity of 38.58%. The business had revenue of $341.57 million during the quarter, compared to analysts' expectations of $297.28 million. On average, research analysts anticipate that BeiGene, Ltd. will post -17.02 EPS for the current fiscal year.
百濟神州(納斯達克代碼：BGNE-GET Rating)最近一次發佈季度收益報告是在8月4日星期四。該公司公佈本季度每股收益為5.56美元，低於分析師普遍預期的4.23美元和1.33美元。百濟神州的淨利潤率為負187.65%，淨資產回報率為負38.58%。該業務本季度營收為3.4157億美元，高於分析師預期的2.9728億美元。研究分析師平均預計，百濟神州有限公司本財年每股收益將達到17.02歐元。
Analyst Ratings Changes
分析師評級發生變化
Institutional Investors Weigh In On BeiGene
機構投資者看好百濟神州
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Koshinski Asset Management Inc. increased its holdings in shares of BeiGene by 139.6% in the first quarter. Koshinski Asset Management Inc. now owns 242 shares of the company's stock valued at $46,000 after purchasing an additional 141 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in shares of BeiGene in the second quarter valued at about $65,000. Advisors Asset Management Inc. increased its holdings in shares of BeiGene by 26.7% in the first quarter. Advisors Asset Management Inc. now owns 1,244 shares of the company's stock valued at $235,000 after purchasing an additional 262 shares during the period. Desjardins Global Asset Management Inc. increased its holdings in shares of BeiGene by 7.6% in the second quarter. Desjardins Global Asset Management Inc. now owns 1,523 shares of the company's stock valued at $246,000 after purchasing an additional 107 shares during the period. Finally, Laurel Wealth Advisors Inc. acquired a new position in shares of BeiGene in the fourth quarter valued at about $249,000. 51.77% of the stock is currently owned by hedge funds and other institutional investors.
一些對衝基金和其他機構投資者最近增持或減持了該業務的股份。今年第一季度，科辛斯基資產管理公司增持了139.6%的百濟神州股票。Koshinski Asset Management Inc.在此期間又購買了141股，目前持有242股該公司股票，價值4.6萬美元。Steward Partners Investment Consulting LLC在第二季度收購了百濟神州的新股票頭寸，價值約65,000美元。Advisors Asset Management Inc.今年第一季度增持了26.7%的百濟神州股票。Advisors Asset Management Inc.在此期間又購買了262股，現在擁有1,244股該公司股票，價值23.5萬美元。Desjardins Global Asset Management Inc.在第二季度增持了7.6%的百濟神州股票。Desjardins Global Asset Management Inc.在此期間又購買了107股，目前持有1,523股該公司股票，價值24.6萬美元。最後，Laurel Wealth Advisors Inc.在第四季度增持了價值約249,000美元的百濟神州股票。51.77%的股票目前由對衝基金和其他機構投資者持有。
About BeiGene
關於百濟神州
(Get Rating)
(獲取評級)
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).
百濟神州是一家生物技術公司，專注於在全球範圍內發現、開發、製造各種藥物並將其商業化。其產品包括用於治療復發/難治性(R/R)套細胞淋巴瘤的BRUKINSA；用於治療R/R經典霍奇金淋巴瘤的Tislelizumab；用於治療多發性骨髓瘤的Revlimid；用於治療骨髓增生異常綜合徵、慢性單核細胞白血病和急性髓細胞白血病的VIDAZA；用於治療骨鉅細胞瘤的XGEVA；用於治療急性淋巴細胞白血病的BLINCETO；用於治療R/R多發性骨髓瘤的Kyprolis；用於治療特發性多中心Castleman病的SYLVANT；用於治療神經母細胞瘤的QARZIBA；用於治療各種實體腫瘤的Pamiparib；以及用於治療轉移性結直腸癌、肝癌和非小細胞肺癌(NSCLC)的Povcy。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on BeiGene (BGNE)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 免費獲取斯托克新聞網關於百濟神州的研究報告(BGNE)
- MarketBeat：回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性？
- 小盤股的裁員是樓市的晴雨表嗎？
- 需要關注的2只半導體類股走勢逆轉
- 好市多盈利後價格疲軟是買入的好時機嗎？
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.
接受《百濟神州日報》的新聞和評級-在下面輸入您的電子郵件地址，即可通過MarketBeat.com的免費每日電子郵件時事通訊接收對百濟神州及相關公司的最新新聞和分析師評級的每日摘要。